Global Allergy Immunotherapies Market 2020-2024 | Evolving Opportunities with Aimmune Therapeutics Inc. and ALK-Abelló AS | Technavio

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

The global allergy immunotherapies market is poised to grow by USD 626.77 million during 2020-2024, progressing at a CAGR of about 7% during the forecast period. Request free sample pages

Read the 120-page report with TOC on “Allergy Immunotherapies Market Analysis Report by Product (SCIT and SLIT), Geographic segmentation (APAC, Europe, MEA, North America, and South America), and the Segment Forecasts, 2020-2024”.

The market is driven by the increasing prevalence of allergies. In addition, the growing popularity of SLIT is anticipated to boost the growth of the allergy immunotherapies market.

The prevalence of various types of allergies is increasing around the world. Among them, peanut allergy, does not have any approved therapies currently. This is encouraging several pharmaceutical companies to develop novel SLITs for the treatment of this indication by conducting heavy research. For instance, AR101 is a SLIT, which is being developed by Aimmune Therapeutics. This is proving to be highly safe and effective in treating peanut allergy. Regulatory bodies are expected to grant marketing approval for two other SLITs that are in Phase III of clinical trials in the forthcoming years. Furthermore, vendors are planning to launch more advanced SCITs during the forecast period by incorporating advanced technologies. Thus, the increasing prevalence of allergies is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Allergy Immunotherapies Market Companies:

Aimmune Therapeutics Inc.

Aimmune Therapeutics Inc. operates the business under the Pharmaceuticals segment. The company offers an oral immunotherapy, PALFORZIA. It is indicated for the mitigation of allergic reactions, including anaphylaxis. The company focuses on the development of treatments for peanut and other food allergies.

ALK-Abell³ AS

ALK-Abell³ AS offers products through the following business units: SCIT and SLIT drops, SLIT tablets, and Other products and services. The company offers RAGWITEK, which is an allergen. They also provide GRASTEK, which is an immunotherapy and ODACTRA, which is a sublingual tablet.

Allergy Therapeutics Plc

Allergy Therapeutics Plc operates under various business segments, namely Central Europe, Southern Europe, and ROW. The company offers Pollinex, Acarovac Plus, and Oralvac. Acarovac Plus is a novel microcrystalline tyrosine. Pollinex is a SCIT, which is approved for the treatment of pollen allergy in the UK.

ASIT Biotech SA

ASIT Biotech SA offers products through the Allergy therapeutics business segment. The company develops effective immunotherapies for environmental and food allergy. They provide gp ASIT Plus, which consists of a mixture of natural allergen fragments.

DBV Technologies SA

DBV Technologies SA offers products through the Epicutaneous immunotherapy business segment. The company markets epicutaneous immunotherapy products. They provide Viaskin Peanut, which is an immunotherapeutic skin patch.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Allergy Immunotherapies Market Product Outlook (Revenue, USD Million, 2020-2024)

  • SCIT
  • SLIT

Allergy Immunotherapies Market Geographic Outlook (Revenue, USD Million, 2020-2024)

  • APAC
  • Europe
  • MEA
  • North America
  • South America

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care Include:

Immunohistochemistry Market “ Global Immunohistochemistry Market by end-users (hospitals, diagnostic laboratories, and academic institutes & research organizations) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.


Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]com